Category Archives: AZBio News

Job Alert: Anayst I, QC Chemistry at Celgene

Posted on by

Title:  Analyst I, QC Chemistry-3rd Shift- Phoenix, AZ

celgene logo 2012

Celgene Corporation, recently declared “The #1 Employer in America” by Business Insider, continues to grow!  We are a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries – and growing – we look for talented people to grow our business, advance our science and contribute to our unique culture.

 

Our Phoenix manufacturing site has a need for an experienced QC Chemist for our 3rd shift.  This position performs and documents testing to support routine analysis of utility, raw material, in-process, finished product and stability samples.  This is an FDA Compliant position and performs shift work as assigned.  Approximate shift hours – 3rd Shift 9:00 pm – 7:30 am (M-Th).  Daily work hours may occasionally extend to up to 12 hours. on an as-needed basis.

 

EDUCATION/EXPERIENCE REQUIREMENTS

 

  • Must possess an Associate’s Degree in Science and four years of experience in a regulated, manufacturing environment- cGMP; or Bachelor’s Degree in Science with two years of experience. (Equivalent combination of experience/education is acceptable)
  • Must be experienced in operating general analytical instruments during testing (e.g. TOC, Conductivity, PSA)
  • Must have a strong ability to operate more advanced instrumentation during testing (e.g. HPLC, GC, ICP)
  • Must live in or be willing to relocate to Phoenix, AZ.

 

Celgene Corporation offers an outstanding total rewards package, including base salary/annual bonus/equity (company stock) and a competitive benefit plan (401k match, etc.).

 

Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status.

Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.

 

Please apply on-line to the posting at:    http://bit.ly/1ua5qbf

 

Celgene’s future has never been brighter. We invite you to explore  “The Promise of Celgene” at  http://www.celgene.com/PromiseofCelgene.pdf

 

Valley Fever Drug Treatment Receives Fast-Track Designation by the FDA Under GAIN Act

Posted on by

Arizona Congressmen David Schweikert and Ron Barber were instrumental in helping AZBio Member Valley Fever Solutions receive Fast-Track Designation from the FDA for the potential curative anti-Valley Fever drug  nikkomycin Z (NikZ) as a “qualifying infectious disease product”  (QIDP) under the GAIN Act, which will help move it into clinical trials and eventually help patients.Continue reading→

Flinn Awards Grant to NAU and Flagstaff Medical Center

Posted on by

Flinn Foundation grant to support NAU health partnership

October 2, 20140 Comments

Paul Keim works under the biosafety cabinet in his Northern Arizona University lab.

 

 

 

The Flinn Foundation has awarded $200,000 to Northern Arizona University, which will collaborate with Flagstaff Medical Center on a project identifying how and where people in the community get infected with common germs.

 

“It will be used to link clinical cases of infectious agents to their sources in the community, and projects that are not even conceived at this point will eventually be possible through this work,” said Paul Keim, Regents professor and director of TGEN’s Pathogen Genomics Division.

This project is part of the Translational Health Research Initiative, the formal partnership between NAU and Northern Arizona Healthcare, FMC’s parent company.

“We have identified common goals so that we can work together to improve the health of our communities,” said Mark Carroll, FMC’s interim chief medical officer.

The genome analysis will take place at NAU with continuous consultation with FMC staff, who will help researchers understand the results in the context of a health care setting. This collaboration is expected to improve understanding of exposure to common infections and guide future research efforts to prevent illness.

A critical component of this project is creating a biobank, a collection of tubes in an ultra cold freezer, along with computer files about the specimens. Along with facilitating infectious disease research, the biobank will support future studies and grant submissions.

Robert Trotter, NAU’s associate vice president for Health Research Initiatives, said the THRIVE partnership for community-based health care research could become a model, which could be adopted in other cities and regions.

The Flinn Foundation is a Phoenix-based philanthropic organization, which funds initiatives designed to improve quality of life in Arizona for future generations. The Foundation’s Seed Grants Initiative to Promote Translational Research in Precision Medicine will cover two years of funding for the NAU partnership.

Continue reading→

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioma

Posted on by

Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioma, which comprises approximately eighty percent of all malignant brain tumors. The ODD includes pontine glioma (PG), a devastating form of primary brainstem glioma.Continue reading→